Budesonide occurs as corticosteroid for the treatment of asthma, non-infectious rhinitis (including hay fever & other allergic reaction), & for coarse of action and bar of rhinal polyposis. In addition, these are utilized for inflammatory bowel disease. These are marketed by AstraZeneca as a nasal inhalation by having a marque Rhinocort, as an unwritten inhalation by using a brand Pulmicort, & as an clyster & a modified-release capsule by having the brand Entocort. These are as well sold within concerted by using formoterol (Oxis) in one inhalator, sustaining a brand Symbicort.

Budesonide has the high number 1 pass metabolism. It has efficaciousness in the terminal ileum and the right colon. It has the moo incidence of systemic manifestations than similar medications.